TY - JOUR
T1 - Precision medicine in neurodegeneration
T2 - the IHI-PROMINENT project
AU - Tate, Ashley
AU - Suárez-Calvet, Marc
AU - Ekelund, Mats
AU - Eriksson, Sven
AU - Eriksdotter, Maria
AU - van der Flier, Wiesje M.
AU - Georges, Jean
AU - Kivipelto, Miia
AU - Kramberger, Milica G.
AU - Lindgren, Peter
AU - López, Juan Domingo Gispert
AU - Lötjönen, Jyrki
AU - Persson, Sofie
AU - Pla, Sandra
AU - Solomon, Alina
AU - Thurfjell, Lennart
AU - Wimo, Anders
AU - Winblad, Bengt
AU - Jönsson, Linus
N1 - Funding Information: PROMINENT represents the first project funded by the Innovative Health Initiative (IHI), an extension of the Innovative Medicine Initiative. With the ultimate aim of fostering the translation of health research and innovation into tangible progress for patients and society, the IHI is a collaboration between the European Union and industry associations representing the healthcare sector: COCIR (medical imaging, radiotherapy, health ICT and electromedical industries); EFPIA, including Vaccines Europe (pharmaceutical industry and vaccine industry); EuropaBio (biotechnology industry); and MedTech Europe (medical technology industry). The IHI funds collaborative, innovative, and interdisciplinary projects which have a patient-centered approach. The first call for proposals for projects related to innovation in cancer, neurodegenerative diseases, and health data was issued on June 2022. PROMINENT was notified of their award of grant funding in November, 2022. Publisher Copyright: Copyright © 2023 Tate, Suárez-Calvet, Ekelund, Eriksson, Eriksdotter, Van Der Flier, Georges, Kivipelto, Kramberger, Lindgren, López, Lötjönen, Persson, Pla, Solomon, Thurfjell, Wimo, Winblad and Jönsson.
PY - 2023
Y1 - 2023
N2 - Neurodegenerative diseases are one of the most important contributors to morbidity and mortality in the elderly. In Europe, over 14 million people are currently living with dementia, at a cost of over 400 billion EUR annually. Recent advances in diagnostics and approval for new pharmaceutical treatments for Alzheimer’s disease (AD), the most common etiology of dementia, heralds the beginning of precision medicine in this field. However, their implementation will challenge an already over-burdened healthcare systems. There is a need for innovative digital solutions that can drive the related clinical pathways and optimize and personalize care delivery. Public-private partnerships are ideal vehicles to tackle these challenges. Here we describe the Innovative Health Initiative (IHI) public-private partnership project PROMINENT that has been initiated by connecting leading dementia researchers, medical professionals, dementia patients and their care partners with the latest innovative health technologies using a precision medicine based digital platform. The project builds upon the knowledge and already implemented digital tools from several collaborative initiatives that address new models for early detection, diagnosis, and monitoring of AD and other neurodegenerative disorders. The project aims to provide support to improvement efforts to each aspect of the care pathway including diagnosis, prognosis, treatment, and data collection for real world evidence and cost effectiveness studies. Ultimately the PROMINENT project is expected to lead to cost-effective care and improved health outcomes.
AB - Neurodegenerative diseases are one of the most important contributors to morbidity and mortality in the elderly. In Europe, over 14 million people are currently living with dementia, at a cost of over 400 billion EUR annually. Recent advances in diagnostics and approval for new pharmaceutical treatments for Alzheimer’s disease (AD), the most common etiology of dementia, heralds the beginning of precision medicine in this field. However, their implementation will challenge an already over-burdened healthcare systems. There is a need for innovative digital solutions that can drive the related clinical pathways and optimize and personalize care delivery. Public-private partnerships are ideal vehicles to tackle these challenges. Here we describe the Innovative Health Initiative (IHI) public-private partnership project PROMINENT that has been initiated by connecting leading dementia researchers, medical professionals, dementia patients and their care partners with the latest innovative health technologies using a precision medicine based digital platform. The project builds upon the knowledge and already implemented digital tools from several collaborative initiatives that address new models for early detection, diagnosis, and monitoring of AD and other neurodegenerative disorders. The project aims to provide support to improvement efforts to each aspect of the care pathway including diagnosis, prognosis, treatment, and data collection for real world evidence and cost effectiveness studies. Ultimately the PROMINENT project is expected to lead to cost-effective care and improved health outcomes.
KW - Alzheimer’s disease
KW - biomarkers
KW - clinical decision support
KW - dementia
KW - precision medicine
UR - http://www.scopus.com/inward/record.url?scp=85168295279&partnerID=8YFLogxK
U2 - https://doi.org/10.3389/fneur.2023.1175922
DO - https://doi.org/10.3389/fneur.2023.1175922
M3 - Article
C2 - 37602259
SN - 1664-2295
VL - 14
JO - Frontiers in Neurology
JF - Frontiers in Neurology
M1 - 1175922
ER -